ReviewStem cells international2019
Enhancing Mesenchymal Stromal Cell Immunomodulation for Treating Conditions Influenced by the Immune System.
Review in Stem cells international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Pooled it
- Innate immune functions of bitter taste receptors across physiological systems.Journal of translational medicine · 2026Review
- MSCs-EVs harboring OA immune memory reprogram macrophage phenotype via modulation of the mt-ND3/NADH-CoQ axis for OA treatment.Journal of nanobiotechnology · 2025Article
- Efficacy of IFN-γ-Primed Umbilical Cord-Derived Mesenchymal Stem Cells on Temporomandibular Joint Osteoarthritis.Tissue engineering and regenerative medicine · 2024Article
- Emerging of a new CD3Frontiers in immunology · 2023Article
- Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches.Journal of Zhejiang University. Science. B · 2022Review
- Understanding the Transcriptomic Landscape to Drive New Innovations in Musculoskeletal Regenerative Medicine.Current osteoporosis reports · 2022Review
- Robust In Vitro and In Vivo Immunosuppressive and Anti-inflammatory Properties of Inducible Caspase-9-mediated Apoptotic Mesenchymal Stromal/Stem Cell.Stem cells translational medicine · 2022Article
- IFN-Gamma and TNF-Alpha as a Priming Strategy to Enhance the Immunomodulatory Capacity of Secretomes from Menstrual Blood-Derived Stromal Cells.International journal of molecular sciences · 2021Article
- An update on extra-oral bitter taste receptors.Journal of translational medicine · 2021Review
- Human umbilical cord mesenchymal stem cells in type 2 diabetes mellitus: the emerging therapeutic approach.Cell and tissue research · 2021Review
- Tumor-resident adenosine-producing mesenchymal stem cells as a potential target for cancer treatment.Clinical and experimental medicine · 2021Review
- Magnetic stimulation of the angiogenic potential of mesenchymal stromal cells in vascular tissue engineering.Science and technology of advanced materials · 2021Article
- Immunomodulating Profile of Dental Mesenchymal Stromal Cells: A Comprehensive Overview.Frontiers in oral health · 2021Article
- Novel insights for improving the therapeutic safety and efficiency of mesenchymal stromal cells.World journal of stem cells · 2020Review
- IL-17 Triggers Invasive and Migratory Properties in Human MSCs, while IFNy Favors their Immunosuppressive Capabilities: Implications for the "Licensing" Process.Stem cell reviews and reports · 2020Article
- Mesenchymal stromal cells for sepsis and septic shock: Lessons for treatment of COVID-19.Stem cells translational medicine · 2020Article
- Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress.Stem cell research & therapy · 2020Review
- Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity.Journal for immunotherapy of cancer · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stromal cells (MSCs), formerly known as mesenchymal stem cells, are nonhematopoietic multipotent cells and are emerging worldwide as the most clinically used and promising source for allogeneic cell therapy. MSCs, initially obtained from bone marrow, can be derived from several other tissues, such as adipose tissue, placenta, and umbilical cord. Diversity in tissue sourcing and manufacturing procedures has significant effects on MSC products. However, in 2006, a minimal set of standard criteria has been issued by the International Society of Cellular Therapy for defining derived MSCs. These include adherence to plastic in conventional culture conditions, particular phenotype, and multilineage differentiation capacity
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.